begacestat
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00441987)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Gamma-secretaseINHIBITOR
Gamma-secretase inhibitor
Thiophene sulfonamide gamma-secretase inhibitor (GSI) that selectively inhibits cleavage of APP over Notch.
Chemistry & pharmacology
Loading structure…
SMILES
O=S(=O)(N[C@H](CO)C(C(F)(F)F)C(F)(F)F)c1ccc(Cl)s1- Mol. weight
- 391.74 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL463981 ↗
Also known as
- begacestat
- begacestat
- begacestat
- begacestat
- gsi-953
- gsi-953
- gsi-953
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00959881 | Phase 1 | Aug 1, 2009 | Pfizer |
| NCT00547560 | Phase 1 | Aug 1, 2007 | Pfizer |
| NCT00479219 | Phase 1 | May 1, 2007 | Pfizer, Wyeth |
| NCT00441987 | Phase 1 | Feb 1, 2007 | Pfizer, Wyeth |
Showing 4 of 4 trials
Page 1 / 1